Page 43 - ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kadmon Holdings, Inc , of Class Action Lawsuit and Upcoming Deadline – KDMN
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
By Travis Whitfill April 23, 2021Reprints
Adobe
Biogen announced its quarterly earnings on April 22 and revealed it had repurchased $600 million of its shares in the first quarter a majority (78%) of its operating cash flow for the quarter. In contrast, Biogen invested a fraction (12%) of its operating cash flow on capital expenditures.
And this was actually a light quarter of share repurchases for Biogen. In 2020, the company repurchased a whopping $6.7 billion of its shares, or 1.67 times its net income of $4 billion for 2020.
One the most critical events in Biogen’s history is looming: the Prescription Drug User Fee Act action date of June 7 the FDA set for aducanumab, its drug for treating Alzheimer’s disease. Despite aducanumab’s somewhat controversial history, Alzheimer’s disease imposes a huge disease burden on society, affecting millions of Americans and their caregivers. It is also among the top 10 causes of death around the world.
(0)
NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the
Journal of Clinical Oncology. A New Drug Application (NDA) for belumosudil is currently under Priority Review by the U.S Food and Drug Administration (FDA) for the treatment of patients with cGVHD, with a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2021. The results from our first clinical study in cGVHD demonstrated that belumosudil achieves meaningful, long-lasting responses and is very well tolerated in refractory cGVHD patients, said Harlan W. Waksal, M.D., President and CEO of Kadmon. These positive results were replicated in the ROCKstar pivotal trial and support belumosudil s ability to offer meaningful clinical benefit, if approved, to patients with cGVHD, for which new therapies